Haleon (LON:HLN) Reaches New 1-Year Low - What's Next?

Key Points

• Haleon shares plunged 15.6%, reaching a new 52-week low of GBX 315.20 versus a previous close of GBX 374, amid exceptionally high trading volume.
• Analyst sentiment is mixed: two analysts rate the stock Buy, one Hold and two Sell. The overall consensus is Hold, with a target price of GBX 387.80—well above the latest trading level.
• Haleon reported quarterly EPS of GBX 8.60, with a 14.55% net margin and 9.89% return on equity; analysts expect full-year EPS of approximately GBX 19.50.

Haleon plc (LON:HLN - Get Free Report)'s share price hit a new 52-week low during trading on Thursday. The company traded as low as GBX 315.20 and last traded at GBX 315.49, with a volume of 1,008,922,813 shares traded. The stock had previously closed at GBX 374.

Wall Street Analyst Weigh In

HLN has been the topic of a number of recent research reports. Berenberg Bank boosted their price objective on Haleon from GBX 512 to GBX 514 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft dropped their target price on Haleon from GBX 335 to GBX 320 and set a "sell" rating for the company in a report on Wednesday, September 9th. Royal Bank Of Canada raised their target price on Haleon from GBX 370 to GBX 390 and gave the stock a "sector perform" rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a GBX 400 price target on shares of Haleon in a report on Friday, July 31st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Haleon has a consensus rating of "Hold" and a consensus target price of GBX 387.80.

Haleon Trading Down 15.6%

The company has a market cap of £27.75 billion, a PE ratio of 17.43, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a quick ratio of 0.93, a current ratio of 0.69 and a debt-to-equity ratio of 50.38. The business has a 50-day simple moving average of GBX 354.60 and a 200-day simple moving average of GBX 360.88.

Haleon (LON:HLN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. On average, analysts predict that Haleon plc will post 19.50 EPS for the current fiscal year.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.